Hematologic Malignancy
Chronic Lymphocytic Leukemia
CI-CAN-00002362BCLL · CLLExplore in graph →
Hematologic265 active trials6 approved drugs46 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00002362BCLL · CLLExplore in graph →
Clinical trials
1,256 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (239)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00078234 | Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 25 | Genta IncorporatedINDUSTRY | 1 | Nov 7, 2011 | clinicaltrials |
| NCT00073489 | A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 23 | Astellas Pharma IncINDUSTRY | 1 | Oct 17, 2011 | clinicaltrials |
| NCT01051115 |
| Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease(D'ACCORD) |
| unknown |
| Phase 2 |
| 35 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER |
| 1 |
| Aug 31, 2011 |
| clinicaltrials |
| NCT01423032 | Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 / Phase 3 | 96 | WiSP Wissenschaftlicher Service Pharma GmbHOTHER | 1 | Aug 25, 2011 | clinicaltrials |
| NCT00524667 | HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia | terminated | Phase 2 | 6 | CancerCare ManitobaOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT01125787 | Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab | terminated | Phase 2 | 1 | Nevada Cancer InstituteOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT01131247 | PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab | withdrawn | Phase 2 | 37 | Nevada Cancer InstituteOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT00275431 | Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies | completed | Phase 2 | 50 | Ascenta TherapeuticsINDUSTRY | 1 | Jun 29, 2011 | clinicaltrials |
| NCT00193518 | Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 2 | 41 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2011 | clinicaltrials |
| NCT00772811 | Using Fludarabine and Melphalan Conditioning Regimen for CLL,Lymphoma,Multiple Myeloma(Flu-Mel) | completed | Phase 2 | 38 | Cooperative Study Group A for HematologyNETWORK | 1 | Feb 17, 2011 | clinicaltrials |
| NCT00285103 | SPC2996 in Chronic Lymphocytic Leukaemia | completed | Phase 1 / Phase 2 | 46 | Santaris Pharma A/SINDUSTRY | 4 | Feb 2, 2011 | clinicaltrials |
| NCT00892827 | Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic Leukemia | unknown | Phase 2 | 10 | Wolfson Medical CenterOTHER_GOV | 1 | Sep 14, 2010 | clinicaltrials |
| NCT00628238 | Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) | unknown | Phase 2 | 80 | Chronic Lymphocytic Leukemia Research ConsortiumNETWORK | 1 | Sep 10, 2010 | clinicaltrials |
| NCT00286780 | Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia | completed | Phase 2 | 19 | Ascenta TherapeuticsINDUSTRY | 1 | Aug 13, 2010 | clinicaltrials |
| NCT00868478 | The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) | unknown | Phase 1 / Phase 2 | 15 | Kaplan Medical CenterOTHER | 1 | Jun 2, 2010 | clinicaltrials |
| NCT00292760 | A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion | completed | Phase 2 | — | Royal Marsden NHS Foundation TrustOTHER | 0 | Dec 16, 2009 | clinicaltrials |
| NCT00021749 | Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 40 | Genta IncorporatedINDUSTRY | 1 | Nov 13, 2009 | clinicaltrials |
| NCT00598624 | Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)(AlloTreo) | unknown | Phase 2 | 175 | IRCCS San RaffaeleOTHER | 1 | Aug 11, 2009 | clinicaltrials |
| NCT00927797 | Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)(PERLL) | unknown | Phase 2 | 185 | Heidelberg UniversityOTHER | 0 | Jun 25, 2009 | clinicaltrials |
| NCT00036023 | Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies | completed | Phase 2 | — | AmgenINDUSTRY | 0 | May 11, 2009 | clinicaltrials |
| NCT00337519 | Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia | unknown | Phase 2 | 82 | Charite University, Berlin, GermanyOTHER | 1 | Jan 29, 2009 | clinicaltrials |
| NCT00800943 | Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy(CRC005) | unknown | Phase 2 | 31 | Chronic Lymphocytic Leukemia Research ConsortiumNETWORK | 1 | Dec 3, 2008 | clinicaltrials |
| NCT00485966 | Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia | withdrawn | Phase 2 | 25 | Cylene PharmaceuticalsINDUSTRY | 1 | Nov 5, 2008 | clinicaltrials |
| NCT00290004 | Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 35 | Pharmacyclics LLC.INDUSTRY | 1 | Sep 11, 2008 | clinicaltrials |
| NCT00676871 | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL) | withdrawn | Phase 1 / Phase 2 | 30 | MedImmune LLCINDUSTRY | 0 | Sep 5, 2008 | clinicaltrials |
| NCT00302861 | A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) | terminated | Phase 1 / Phase 2 | 86 | Genitope CorporationINDUSTRY | 0 | Mar 18, 2008 | clinicaltrials |
| NCT00109356 | Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia | unknown | Phase 1 / Phase 2 | 55 | NovaceaINDUSTRY | 1 | May 7, 2007 | clinicaltrials |
| NCT00058656 | Autologous T Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) Patients | completed | Phase 1 / Phase 2 | 18 | Xcyte TherapiesINDUSTRY | 1 | Nov 22, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Nov 7, 2011source: clinicaltrials